HUNGARY today
Gedeon Richter Nyrt. reported first-half results in line with its annual targets, prompting the company to maintain its 2025 growth forecast, CEO Gábor Orbán said Wednesday in Budapest.
Adjusting for currency fluctuations, the pharmaceutical giant anticipates approximately 10% growth in both revenue and adjusted EBIT for the year. Pharmaceutical manufacturing, which accounts for 98% of sales, rose 11% in the second quarter to 237.5 billion HUF (cc. 598 million EUR/1 EUR = 397 HUF), bringing half-year revenue to 458 billion HUF.
